Latest Issue

Delivering Injectables: Devices & Formulations 186

Issue No #186 May 2026 May 19th, 2026

Issue 186 - May 2026

Inside the magazine

Interview: Celebrating 10 Years of Molly Enabling Patients’ Independence

Nicholas Heaton

Interview: Celebrating 10 Years of Molly Enabling Patients’ Independence

Nicholas Heaton looks back on the decade since Molly – SHL Medical’s signature two-step autoinjector platform – was launched onto the market, reviewing what made the device platform a success, where Molly is positioned in the market today and how it will continue to evolve to meet the demands of the future.

FROM SMALL TO LARGE MOLECULES: ADVANCING PRECISION PUMP TECHNOLOGY FOR BIOLOGIC DRUG DELIVERY

Dr Ines Rüstenberg

FROM SMALL TO LARGE MOLECULES: ADVANCING PRECISION PUMP TECHNOLOGY FOR BIOLOGIC DRUG DELIVERY

Dr Ines Rüstenberg, Roger Müller and Dr Yannick Schmid, discuss solutions for large-molecule drug delivery, highlighting the applicability of two infusors, Gx InPuls and Gx InPuls Flex, which employ micropump technology to overcome challenges with large-molecule delivery.

Interview: GLP-1 Demand and the New Reality of Device Manufacturing Capacity

Interview: GLP-1 Demand and the New Reality of Device Manufacturing Capacity

Andy Wertheim discusses the growing shortage of available manufacturing capacity driven by the boom in GLP-1 therapies, why this means mid-volume development programmes across a range of sectors are struggling to move from development to industrialisation, and how Quvara Medical is ideally positioned to provide the capacity that these programmes lack.

CLOSING THE SAFETY GAP: WHY PHARMA-DEDICATED LABELS MATTER

INDUSTRIALISATION

Paavo Sillanpää

UPM Adhesive Materials

CLOSING THE SAFETY GAP: WHY PHARMA-DEDICATED LABELS MATTER

Paavo Sillanpää discusses why pharma-dedicated labels matter for more challenging labelling applications as well as how to avoid potential label failure and brand risk.

ADVANCING AUTOINJECTOR PLATFORMS FOR EVOLVING DRUG AND PATIENT NEEDS

Martin Høier Thomsen

ADVANCING AUTOINJECTOR PLATFORMS FOR EVOLVING DRUG AND PATIENT NEEDS

Martin Høier Thomsen introduces MGS’s A.i.r. Platform™ within the broader context of the evolution of autoinjector platforms towards more adaptable, customisable solutions. He considers how next-generation autoinjector platforms can address increasingly complex and changing demands, while helping to mitigate risk and prioritise usability.

DELIVERABILITY, ACCEPTABILITY, AVAILABILITY: ASSESSING THE EVOLVING STRENGTHS OF MICRONEEDLE-BASED DRUG DELIVERY

DELIVERABILITY, ACCEPTABILITY, AVAILABILITY: ASSESSING THE EVOLVING STRENGTHS OF MICRONEEDLE-BASED DRUG DELIVERY

Dr May Pidding explores the growth and future potential of microneedle technology and its suitability for a broad range of drug delivery applications, specifically presenting the case for the accelerated uptake and wider adoption of Microneedle Array Patch (MAP) technology.

IMPORTANCE OF BEING PATIENT-CENTRIC IN CARDIOVASCULAR-KIDNEY-METABOLIC CARE

IMPORTANCE OF BEING PATIENT-CENTRIC IN CARDIOVASCULAR-KIDNEY-METABOLIC CARE

Cécile Gross and Mark Tunkel discuss Nemera's substantial portfolio of user-friendly, effective injectable devices available to meet the needs of patients with diverse chronic conditions.

DEORA™: FILLING THE GAP FOR MULTI-USE, FIXED-DOSE INJECTION SOLUTIONS

Stevanato Group

DEORA™: FILLING THE GAP FOR MULTI-USE, FIXED-DOSE INJECTION SOLUTIONS

Manuela Giacon explores the evolution of handheld drug delivery devices, leading up to today’s challenges, and presents the company’s latest addition to its drug delivery portfolio.

LVSC DELIVERY: HOW VOLUME AND CONCENTRATION REQUIREMENTS ARE RESHAPING DEVICE SELECTION

Phillips Medisize

LVSC DELIVERY: HOW VOLUME AND CONCENTRATION REQUIREMENTS ARE RESHAPING DEVICE SELECTION

Tony Bedford considers how the rise in biologic formulations together with a strong shift towards subcutaneous administration is shaping the drug delivery industry, particularly in relation to large-volume subcutaneous delivery.

AUTOINJECTOR TECHNOLOGY FOR AUTOMATIC MICROPARTICLE SUSPENSION AND INJECTION

Girum Yemane-Tekeste

AUTOINJECTOR TECHNOLOGY FOR AUTOMATIC MICROPARTICLE SUSPENSION AND INJECTION

Girum Yemane-Tekeste and Stephen Leslie share how Kindeva is building on its experience and history of innovation to develop an enabling technology for injectable microparticles and then evaluating it through proof-of-principle testing.

EARLY DECISIONS, FASTER LAUNCH: OPTIMISING COMBINATION PRODUCT COMMERCIALISATION

PCI Pharma Services

EARLY DECISIONS, FASTER LAUNCH: OPTIMISING COMBINATION PRODUCT COMMERCIALISATION

Bill Welch explores how early development selections, structured timelines and adoption of a “path of least resistance” can reduce technical, regulatory and commercial risk, thereby optimising product commercialisation.

INJECTABLE COLLAGEN – PRESENT AND FUTURE POTENTIAL

Martin Junginger

INJECTABLE COLLAGEN – PRESENT AND FUTURE POTENTIAL

Martin Junginger discusses the advantages and challenges of delivering collagen via injection, considering the role that collagen plays in the current healthcare landscape, including GELITA's VACCIPRO^® and MEDELLAPRO^® collagen grades, and sharing insights on how that role may grow and adapt going forwards.

EXCIPIENT LANDSCAPES: HIGH-THROUGHPUT SCREENING TO SOLVE VISCOSITY BOTTLENECKS FOR BIOLOGIC THERAPEUTICS

Dr Scott Compel

EXCIPIENT LANDSCAPES: HIGH-THROUGHPUT SCREENING TO SOLVE VISCOSITY BOTTLENECKS FOR BIOLOGIC THERAPEUTICS

Dr Scott Compel and Dr Alex Hendricks discuss AEMS Corp's automated, microscale screening platform that enables viscosity reduction, using innovative approaches to test excipient combinations effectively.

SCALING RADIOLIGAND THERAPY: WHY PACKAGING AND DELIVERY SYSTEMS MUST EVOLVE

Dr Eva Littringer

SCALING RADIOLIGAND THERAPY: WHY PACKAGING AND DELIVERY SYSTEMS MUST EVOLVE

Dr Eva Littringer and Dr Roland Starlinger discuss the exciting new frontier of radioligand therapy and the imminent bottleneck presented by current delivery methods running into strict limits on handling radioactive materials. They go on to introduce the Oncofuse prefilled-syringe-based system as a novel approach to containment and handling of these therapies, enabling radioligand therapy to expand beyond niche specialist clinics and hospitals.

CONQUERING COMPLEXITY WITH LIFECORE INJECTABLES

Lifecore Injectables

CONQUERING COMPLEXITY WITH LIFECORE INJECTABLES

Lifecore Injectable, a US-based injectables CDMO, has built a reputation for embracing complex process development and manufacturing challenges that others avoid. This mindset is rooted in the company’s legacy as a manufacturer of sodium hyaluronate, a highly viscous material known for being difficult to filter and fill.

EXPANDING SUBCUTANEOUS DESIGN BRICK BY BRICK: THE BD NEOPAK™ GLASS PREFILLABLE SYRINGE PLATFORM

PREFILLED SYRINGES

Hervé Soukiassian

BD (Becton Dickinson & Company)

EXPANDING SUBCUTANEOUS DESIGN BRICK BY BRICK: THE BD NEOPAK™ GLASS PREFILLABLE SYRINGE PLATFORM

Hervé Soukiassian and Sophie Lelias discuss the established injection platforms built to achieve reliable and efficient subcutaneous delivery, going further to examine new injectable devices in development that are designed for an optimised patient experience as well as higher-volume, higher-viscosity delivery.

TRANSDERMAL DRUG DELIVERY: ENHANCING PERMEABILITY AND IN VIVO TRANSLATION

TRANSDERMAL DRUG DELIVERY: ENHANCING PERMEABILITY AND IN VIVO TRANSLATION

Dr Leo Pan provides insights into the field of transdermal drug delivery and investigates the two primary approaches being taken to advance the sector – enhancing the ability of drugs to permeate through the skin barrier and translating in vitro data to an in vivo reality.

BEYOND THE BARREL: PREFILLED SYRINGES THAT FOLD IN HALF

BEYOND THE BARREL: PREFILLED SYRINGES THAT FOLD IN HALF

Ian Speers, Robert Halvorsen and Ryan Stinebaugh discuss the unmet needs in prefilled deployability that led to the development of Slimshot™, a detached plunger rod that nests alongside the syringe, and Slimshot™ Doser, a companion concept designed to reduce the mental load of variable dosing in high-pressure delivery situations, and how these concepts can contribute to improved workflows and logistics throughout the healthcare sector.

ANTIBODY-DRUG CONJUGATES: AN EMERGING FRONTIER IN IV TO SC CONVERSION

ANTIBODY-DRUG CONJUGATES: AN EMERGING FRONTIER IN IV TO SC CONVERSION

Dr Mehul Desai, Dr Michael Hageman and Dr Wei Chen examine the growing antibody-drug conjugate market, the unique formulation challenges these therapies present for subcutaneous delivery and how innovations in on-body injector technology may offer a practical path forwards.

STERILE DRUG PRODUCTION: AN EVER-EVOLVING MARKET

Norbert Kübler

STERILE DRUG PRODUCTION: AN EVER-EVOLVING MARKET

Dr Norbert Kübler discusses the current state of sterile drug products, considering how advancing technology is changing the field, the role of quality control and the challenges faced during scale-up and manufacturing.

Top